

December 3, 2024



# Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.

## ***Presentation Details:***

Date: December 5, 2024  
Time: 10:30-10:55 am Eastern Time  
Location: Lotte New York Palace, NY, NY

## **About Monopar Therapeutics Inc.**

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: [www.monopartx.com](http://www.monopartx.com).

## **CONTACT:**

### **Monopar Therapeutics Inc.**

Investor Relations  
Karthik Radhakrishnan  
Chief Financial Officer  
[karthik@monopartx.com](mailto:karthik@monopartx.com)

Follow Monopar on social media for updates:  
Twitter: [@MonoparTx](https://twitter.com/MonoparTx) LinkedIn: [Monopar Therapeutics](https://www.linkedin.com/company/monopar-therapeutics)



Source: Monopar Therapeutics Inc.